Cardinal Health (CAH)
NYSE: CAH · Medical Distribution · Dublin, OH
Our rating: Neutral
Call changed from Positive to Neutral at $271.72, moderate conviction, November 6, 2026.
Breaks if: For a Neutral call, two conditions would change the view in opposite directions. It turns Positive if free cash flow sustains above $5.5B for two consecutive annual reporting periods — implying the structural float advantage is widening and the FCF yield rises above roughly 8.5% at today's price — alongside evidence of net margin expanding toward 1%. It turns Cautious if free cash flow drops below $3B for two straight annual periods, dragging the FCF yield below 5% at today's price, or if revenue growth decelerates below 8% year-on-year within the next four quarters, suggesting the specialty drug volume tailwind has stalled before the valuation has re-priced.
Key figures
| Market value | $63.1B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | n/a |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.8% |
| Operating margin | n/a |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.23 |
| Volatility, annualized | 25.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $67.5B | 5.5% | $2.38 | $1.2B |
| December 31, 2025 | $65.6B | 18.8% | n/a | $555M |
| September 30, 2025 | $64.0B | 22.4% | $1.88 | $865M |
| June 30, 2025 | $60.2B | 0.5% | n/a | $1.3B |
| March 31, 2025 | $54.9B | 0.0% | n/a | $2.8B |
| December 31, 2024 | $55.3B | −3.8% | n/a | −$495M |
| September 30, 2024 | $52.3B | −4.3% | $1.70 | −$1.7B |
| June 30, 2024 | $59.9B | 12.1% | n/a | $1.9B |
8 ledger entries and 62 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.